Insomnia and inflammation in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

Autor: Miller BJ; Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA, United States. Electronic address: brmiller@augusta.edu., McCall WV; Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA, United States., McEvoy JP; Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA, United States., Lu XY; Department of Neuroscience and Regenerative Medicine, Augusta University, Augusta, GA, United States.
Jazyk: angličtina
Zdroj: Psychiatry research [Psychiatry Res] 2021 Nov; Vol. 305, pp. 114195. Date of Electronic Publication: 2021 Aug 29.
DOI: 10.1016/j.psychres.2021.114195
Abstrakt: Insomnia and inflammation are both common in schizophrenia. In the general population, insomnia is associated with inflammation. In n=519 subjects from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial, terminal insomnia was investigated as an indicator of inflammation using non-parametric ANCOVA. After controlling for potential confounders, insomnia was significantly associated with higher blood IL-6 (F=4.12, p=0.007) and leptin (F=9.67, p<0.001) with large effect sizes (d=1.03 and d=0.79, respectively). Findings suggest that the assessment of insomnia is relevant to studies of inflammation in schizophrenia, and germane to trials of adjunctive hypnotics and anti-inflammatory agents in these patients.
(Copyright © 2021. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: